Discover Absci Corporation's Q1 2025 earnings highlights: clinical trial milestones, AI-driven biotech innovation, and strong financial outlook.

Ceftazidime-avibactam and ceftolozane-tazobactam were the most commonly prescribed antibiotics of all broad-spectrum agents approved in the past decade.